ESMO 2023

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

ESMO 2023
Jun 7, 2024, 11:30 | Blog
Exploring IMDC Treatment Strategies at ESMO 2024 with Professor Manuela Schmidinger - MediaMedic
MediaMedic posted on LinkedIn: "Exploring IMDC Treatment Strategies at ESMO 2023. Oncology Frontier interviewed Professor…
May 15, 2024, 04:12 | Blog
Tanja Obradovic: News about effectiveness of PD-1 inhibitors in endometrial cancer continues to paint complex picture
Tanja Obradovic shared on LinkedIn: ''News about effectiveness of PD-1 inhibitors in endometrial cancer continues…
Mar 7, 2024, 18:04 | Blog
Check out the latest 2 podcasts on lung cancer and psycho-oncological perspective- European School of Oncology
European School of Oncology shared a post on LinkedIn: "Check out the latest 2 podcasts:…
Nov 30, 2023, 16:23 | Drugs
Mariana Brandao: My comment on the ARTEMIDE-01 phase I trial testing a new bispecific anti-PD-1/anti-TIGIT antibody called Rilvegostomig
Mariana Brandao, a Medical Oncologist at Institut Jules Bordet, recently shared on LinkedIn: "Here's my…
Nov 25, 2023, 17:59 | Drugs
Andrew Pannu: The ADC space is blowing up
Andrew Pannu posted on LinkedIn: "The ADC space is blowing up: • More than $125B in…
Nov 4, 2023, 00:25 | Insight
María Natalia Gandur Quiroga: After a successful ESMO 23, ADC continues to shine
María Natalia Gandur Quiroga shared a post on X/Twitter: “After a successful ESMO 23, ADC…
Oct 31, 2023, 16:15 | Insight
Svetlana Nikic: Congratulations to the scientific committee for an excellent ESMO 2023
Svetlana Nikic, Founder of Precision Oncology Consulting, shared on her LinkedIn: "Congratulations to the scientific committee…
Oct 30, 2023, 07:33 | Blog
Sebastian Werngreen Nielsen: This weekend I had the privilege of attending the ESMO 2023 conference in Madrid as an invited speaker and poster presenter
Quoting Sebastian Werngreen Nielsen, MD at Rigshospitalet Copenhagen University Hospital, on LinkedIn: "This weekend I…
Oct 29, 2023, 03:16 | Drugs
Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "ESMO23 is…
Oct 28, 2023, 15:34 | Blog
Andreas A. Argyriou: Honoured to be an invited speaker at the Madrid ESMO 2023 and present about chemotherapy-induced central neurotoxicity
Andreas A. Argyriou, Neurology Medical Director at Agios Andreas State General Hospital, shared a post o…
Oct 27, 2023, 04:48 | Insight
Sumanta K. Pal: Eloquent discussion from Andrea Apolo National Cancer Institute synthesizing data from EV302 and CM901
Sumanta K. Pal, Co-Director of the City of Hope Kidney Cancer Program, posted on Twitter: "Eloquent…
Oct 25, 2023, 18:09 | Blog
Joanna Dodkins: Very excited to be presenting work conducted at the National Prostate Cancer Audit
Joanna Dodkins, Clinical oncology registrar at Guy's Hospital, London, shared on her Twitter: "Very excited to…
Oct 24, 2023, 16:09 | Societies
ESMO congratulates the recipients of the 2023 Research Fellowships and the José Baselga Fellowship
ESMO posted on their Twitter page: "ESMO congratulates the recipients of the 2023 Research Fellowships…
Oct 24, 2023, 15:57 | Blog
Kathrin Heinrich: Why is there no applause for this KM-curve…?
Kathrin Heinrich, Doctor at the Ludwig Maximilian University Hospital, Munich, recently tweeted: "Why is there no…
Oct 24, 2023, 15:49 | Blog
Benedikt Westphalen: First results of CUPISCO presented at ESMO23
Quoting Benedikt Westphalen, Medical Lead Precision Oncology, on X/Twitter: "First results of CUPISCO presented at…
Oct 23, 2023, 17:15 | Insight
María Natalia Gandur Quiroga: Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991 study results.
Quoting María Natalia Gandur Quiroga on X/Twitter: “Disappointing update from ESMO 23: Christina Gratzke reveals KEYNOTE-991…
Oct 23, 2023, 15:35 | Blog
Julien Mazières: Alectinib is the first ALK inhibitor to significantly improve DFS compared with CT
Julien Mazières, Thoracic Oncology Specialist at Toulouse University Hospital, France, shared insights from the ALINA…
Oct 23, 2023, 15:24 | Insight
Why radiotherapy with concomitant chemotherapy is an excellent option for bladder preservation in bladder cancer patients
Pierre Blanchard, Full Professor of Radiation Oncology at Gustave Roussy Cancer Center, posted on his…
Oct 23, 2023, 13:31 | Drugs
At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational botensilimab/balstilimab combination in relapsed/refractory sarcoma
Agenus shared on their LinkedIn page: "At ESMO 2023 Dr. Breelyn Wilky presented new data from our investigational…
Oct 22, 2023, 17:15 | Blog
Advanced Oncology discussed the humanitarian crisis linked to the invasion of Artsakh with Davit Zohrabyan
Advanced Oncology shared a post on LinkedIn: “At such a big meeting like ESMO 2023…
Oct 22, 2023, 17:00 | Blog
Ravindran Kanesvaran: Great start to ESMO 2023 day 1!
Ravindran Kanesvaran, Deputy Chair and Senior Consultant, Division of Medical Oncology at National Cancer Centre…
Oct 21, 2023, 19:19 | Blog
Akash Maniam: Personally, the neoadjuvant IO data in early breast cancer is the most intriguing
Akash Maniam, a Medical Oncologist at Portsmouth Hospitals University NHS Trust, and the Clinical Director…
Oct 21, 2023, 19:00 | Blog
Yelena Janjigian: A new treatment for patients with HER2+ gastroesophageal cancer in Europe, US and Brazil
Yelena Janjigian posted on her LinkedIn: "From preclinical rationale to our Memorial Sloan Kettering Cancer Center…
Oct 19, 2023, 18:39 | Blog
Paolo Tarantino: The BEGONIA ph1/2 trial ages like good wine
Quoting Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, on X/Twitter: “The BEGONIA ph1/2 trial…
All: 24 Posts: 1 - 100
Special Coverage